Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis

Brain

Volumn 121, Issue 8, 1998, Pages 1395-1407

  Zipp, Frauke ^a   Kerschensteiner, Martin ^a   Dornmair, Klaus ^a   Malotka, Joachim ^a   Schmidt, Stephan ^a   Bender, Anke ^a   Giegerich, Gerhard ^a   De Waal Malefyt, René ^c   Wekerle, Hartmut ^a   Hohlfeld, Reinhard ^a,b  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Autoimmune disease; Immunotherapy; Multiple sclerosis

Indexed keywords

CD4 ANTIGEN; HLA DR ANTIGEN; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR;

ARTICLE; CHROMATOGRAPHY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOID CELL LINE; MULTIPLE SCLEROSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PURIFICATION; T LYMPHOCYTE; VACCINATION;

EID: 0031853145     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/121.8.1395     Document Type: Article

References (49)

1. Antel JP, Becher B, Owens T. Immunotherapy for multiple sclerosis [comment]. Nature Med 1996; 2: 1074-5. Comment on: Nat Med 1996; 2: 1109-15.
2. Antel JP, Becher B, Owens T. Immunotherapy for multiple sclerosis [comment]. Nature Med 1996; 2: 1074-5. Comment on: Nat Med 1996; 2: 1109-15.
3. Ben-Nun A, Cohen IR. Vaccination against autoimmune encephalomyelitis (EAE): attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line. Eur J Immunol 1981; 11: 949-52.
4. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with a T-lymphocyte line reactive against myelin basic protein. Nature 1981; 292: 60-1.
5. Breedveld FC, Struyk L, van Laar JM, Miltenburg AM, De Vries RR, van den Elsen PJ. Therapeutic regulation of T cells in rheumatoid arthritis. [Review]. Immunol Rev 1995; 144: 5-16.
6. Broeren CP, Lucassen MA, van Stipdonk MJ, van der Zee R, Boog CJ, Kusters JG, et al. CDR1 T-cell receptor β-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions. Proc Natl Acad Sci USA 1994; 91: 5997-6001.
7. Chicz RM, Urban RG. Analysis of MHC-presented peptides: applications in autoimmunity and vaccine development. [Review]. Immunol Today 1994; 15: 155-60.
8. Chunduru SK, Sutherland RM, Stewart GA, Doms RW, Paterson Y. Exploitation of the Vβ8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector, J Immunol 1996; 156: 4940-5.
9. Cohen IR. The cognitive paradigm and the immunological homunculus. [Review]. Immunol Today 1992; 13: 490-4.
10. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. [Review]. Cell 1994; 76: 287-99.
11. Giegerich G, Pette M, Meinl E, Epplen JT, Wekerle H, Hinkkanen A. Diversity of T cell receptor α and β chain genes expressed by human T cells specific for similar myelin basic protein peptide/major histocompatibility complexes [published erratum appears in Eur J Immunol 1992; 22: 1331]. Eur J Immunol 1992; 22: 753-8.
12. Gold DP, Smith RA, Golding AB, Morgan EE, Dafashy T, Nelson J, et al. Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRVβ6 CDR2 peptide. J Neuroimmunol 1997; 76: 29-38.
13. Hafler DA, Saadeh MG, Kuchroo VK, Milford E, Steinman L. TCR usage in human and experimental demyelinating disease [Review]. Immunol Today 1996; 17: 152-9.
14. Hawke S, Matsuo H, Nicolle M, Malcherek G, Melms A, Willcox N. Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. [Review]. Immunol Today 1996; 17: 307-11.
15. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. [Review]. Brain 1997; 120: 865-916.
16. Hohlfeld R, Meinl E, Weber F, Zipp F, Schmidt S, Sotgiu S, et al. The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. [Review]. Neurology 1995; 45(6 Suppl 6): S33-8.
17. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides [published erratum appears in Science 1990; 247: 1167]. Science 1989; 246: 668-70.
18. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974; 125C: 373-89.
19. Kourilsky P, Chaouat G, Rabourdin-Combe C, Claverie J-M. Working principles in the immune system implied by the 'peptide-self model. Proc Natl Acad Sci USA 1987; 84: 3400-4.
20. Kumar V, Tabibiazar R, Geysen HM, Sercarz E. Immunodominant framework region 3 peptide from TCR Vβ8.2 chain controls murine experimental autoimmune encephalomyelitis. J Immunol 1995; 154: 1941-50.
21. Kumar V, Stellrecht K, Sercarz EE. Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE). J Exp Med 1996; 184: 1609-17.
22. Kumar V, Coulsell E, Ober B, Hubbard G, Sercarz E, Ward ES. Recombinant T cell receptor molecules can prevent and reverse experimental autoimmune encephalomyelitis. J Immunol 1997; 159: 5150-6.
23. Lamb JR, Feldmann M. A human suppressor T cell clone which recognizes an autologous helper T cell clone. Nature 1982; 300: 456-8.
24. Lanzavecchia A, Roosnek E, Gregory T, Berman P, Abrignani S. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature 1988; 334: 530-2.
25. LaSalle JM, Ota K, Hafler DA. Presentation of autoantigen by human T cells. J Immunol 1991; 147: 774-80.
26. Lider O, Reshef T, Béraud E, Ben-Nun A, Cohen IR. Anti-idiotypic network induced by T-cell vaccination against experimental autoimmune encephalomyelitis. Science 1988; 239: 181-3.
27. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. [Review]. Annu Rev Immunol 1992; 10: 153-87.
28. Matsuo H, Batocchi A-P, Hawke S, Nicolle M, Jacobson L, Vincent A, et al. Peptide-selected T cell lines from myasthenia gravis patients and controls recognize epitopes that are not processed from whole acetylcholine receptor. J Immunol 1995; 155: 3683-92.
29. Medaer R, Stinissen P, Truyen L, Raus J, Zhang J. Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis. Lancet 1995; 346: 807-8.
30. Meinl E, Weber F, Drexler K, Morelle C, Ott M, Saruhan-Direskeneli G, et al. Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis: complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. J Clin Invest 1993; 92: 2633-43.
31. Mohagheghpour N, Damle NK, Tanaka S, Engleman EG. Generation of antigen receptor-specific suppressor T cell clones in man. J Exp Med 1986; 164: 950-5.
32. Pette M, Fujita K, Wilkinson D, Altmann DM, Trowsdale J, Giegerich G, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990; 87: 7968-72.
33. Pichler WJ, Wyss-Coray T. T cells as antigen-presenting cells. [Review]. Immunol Today 1994; 15: 312-5.
34. Rammensee H-G. Chemistry of peptides associated with MHC class I and class II molecules. [Review]. Curr Opin Immunol 1995; 7: 85-96.
35. Richert JR, Robinson ED, Camphausen K, Martin R, Voskuhl RR, Faerber MA, et al. Diversity and T-cell receptor Vα, Vβ, and CDR3 expression by myelin basic protein-specific human T-cell clones. Neurology 1995; 45: 1919-22.
36. Romagnani S. Lymphokine production by human T cells in disease states. [Review]. Annu Rev Immunol 1994; 12: 227-57.
37. Samelson LE, Harford J, Schwartz RH, Klausner RD. A 20-kDa protein associated with the murine T cell antigen receptor is phosphorylated in response to activation by antigen or concanavalin A. Proc Natl Acad Sci USA 1985; 82: 1969-73.
38. + cells recognizing epitopes of the T cell receptor β chain from a myelin basic protein-specific T cell clone. Eur J Immunol 1993; 23: 530-6.
39. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of nonspecific cells: a tale of smart bombs and the infantry. [Review]. Proc Natl Acad Sci USA 1996; 93: 2253-6.
40. Sun D, Qin Y, Chluba J, Epplen JT, Wekerle H. Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions. Nature 1988; 332: 843-5.
41. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 1989; 341: 541-4.
42. Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeid D, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial [see comments] [published erratum appears in Nat Med 1997; 3: 240]. Nature Med 1996a; 2: 1109-1115. Comment in: Nat Med 1996; 2: 1074-5.
43. Vandenbark AA, Chou YK, Whitham R, Mass M, Buenafe A, Liefeid D, et al. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial [see comments] [published erratum appears in Nat Med 1997; 3: 240]. Nature Med 1996a; 2: 1109-1115. Comment in: Nat Med 1996; 2: 1074-5.
44. Vandenbark AA, Hashim GA, Offner H. T cell receptor peptides in treatment of autoimmune disease: rationale and potential. [Review]. J Neurosci Res 1996b; 43: 391-402.
45. Waisman A, Ruiz PJ, Hirschberg DL, Gelman A, Oksenberg JR, Brocke S, et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity [see comments]. Nat Med 1996; 2: 899-905. Comment in: Nat Med 1996; 2: 857-9.
46. Waisman A, Ruiz PJ, Hirschberg DL, Gelman A, Oksenberg JR, Brocke S, et al. Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity [see comments]. Nat Med 1996; 2: 899-905. Comment in: Nat Med 1996; 2: 857-9.
47. Wekerle H, Kojima K, Lannes-Vieira J, Lassmann H, Linington C. Animal models. [Review]. Ann Neurol 1994; 36 Suppl: S47-53.
48. Wessel D, Flügge UI. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984; 138: 141-3.
49. Wilson DB, Golding AB, Smith RA, Dafashy T, Nelson J, Carlo DJ, et al. Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T cell receptor utilization in CSF cell populations. J Neuroimmunol 1997; 76: 15-28.